FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

@article{Taeb2007FOLFIRI3AN,
  title={FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.},
  author={Julien Ta{\"i}eb and Thierry Lecomte and Thomas Aparicio and Amani Asnacios and Touraj Mansourbakht and Pascal Artru and David Fallik and J P Spano and Bruno Landi and G{\'e}rard Lledo and J{\'e}r{\^o}me Desram{\'e}},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2007},
  volume={18 3},
  pages={498-503}
}
BACKGROUND The purpose of the study was to prospectively evaluate the efficacy and tolerability of the FOLFIRI.3 regimen in patients with unresectable pancreatic adenocarcinoma. PATIENTS AND METHODS Chemotherapy-naive patients with histologically proven advanced pancreatic adenocarcinoma were treated with the FOLFIRI.3 regimen, consisting of irinotecan 90 mg/m(2) as a 60-min infusion on day 1, leucovorin 400 mg/m(2) as a 2-h infusion on day 1, followed by 5-fluorouracil (5-FU) 2000 mg/m(2) as… CONTINUE READING
23 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…